APA (7th ed.) Citation

SP, U., CF, T., CJ, H., EA, E., CA, A., MP, C., . . . A, K. (2022). Analysis of residual disease in periocular basal cell carcinoma following hedgehog pathway inhibition: Follow up to the VISORB trial. PloS one, 17(12), e0265212. https://doi.org/10.1371/journal.pone.0265212

Chicago Style (17th ed.) Citation

SP, Unsworth, Tingle CF, Heisel CJ, Eton EA, Andrews CA, Chan MP, Bresler SC, and Kahana A. "Analysis of Residual Disease in Periocular Basal Cell Carcinoma Following Hedgehog Pathway Inhibition: Follow Up to the VISORB Trial." PloS One 17, no. 12 (2022): e0265212. https://doi.org/10.1371/journal.pone.0265212.

MLA (9th ed.) Citation

SP, Unsworth, et al. "Analysis of Residual Disease in Periocular Basal Cell Carcinoma Following Hedgehog Pathway Inhibition: Follow Up to the VISORB Trial." PloS One, vol. 17, no. 12, 2022, p. e0265212, https://doi.org/10.1371/journal.pone.0265212.